The European Proteomics Infrastructure Consortium providing access (EPIC-XS), funded as part of the Horizon 2020 Work programme, held its kick-off meeting in Amsterdam on April 25-26 2019. In this article, we discuss the objectives and highlights of the meeting.READ MORE
Francis S. Collins, M.D., Ph.D. Director of the National Institutes of Health, has recently directly addressed the issue of underrepresented groups in science: "Too often, women and members of other groups underrepresented in science are conspicuously missing in the marquee speaking slots at scientific meetings and other high-level conferences.”READ MORE
At Argonne National Laboratory, the Aurora supercomputer will lead the charge as the US's first system exceeding an exaflop, or a billion-billion calculations per second. In this article, we explore how Aurora could enable revolutionary advances in heterogeneous catalysis chemistry research, with implications for fossil fuel processing and small molecule conversion.READ MORE
This article dwells upon the challenges presented by prevailing data visualization solutions for drug discovery and covers how enablers such as AI and VR have transformed the drug discovery data visualization market. It touches upon examples of existing solutions, new players and upcoming industry partnerships.READ MORE
A story of the Elvesys Innovation Unit, a research institute in France designed to unite entrepreneurs involved in microfluidics research.READ MORE
Male contraceptive methods account for just 25% of all contraceptive use worldwide. We recently spoke with Christina Wang, MD and Stephanie Page MD, PhD – involved in the development of two male oral contraceptive drugs. They discuss recent clinical study results, explain how the drugs work, and highlight the various alternative drug delivery methods they are currently investigating.READ MORE
The final instalment of The Evolution of Proteomics series features an interview with Professor John Yates from the Department of Molecular Medicine at Scripps Research. The Yates laboratory is focused on developing strategies and tools in proteomics to answer basic biological questions.
AI is rapidly being adopted in the pharmaceutical industry. Nonetheless, much pharmaceutical development data is limited, resulting in restricted amounts of usable data. Sparse data AI – the application of AI to restricted amounts of data – is opening up novel avenues for enhanced drug development. In this article, Nanoform’s Jukka Corander looks at how sparse data can help pharma industry AI gain greater transparency and lead to more life-changing medicines reaching the market.
In this instalment of The Evolution of Proteomics, we speak with Dr Alexander Makarov, Director of Research in Life Sciences Mass Spectrometry (MS) at Thermo Scientific, and world-renowned inventor of the Orbitrap mass analyzer technology.READ MORE
The question perhaps is not when native mass spectrometry can be used; but rather, when can’t it be used? Today, the applications are broad-reaching and diverse. This article shares insights from innovators in the field who have helped establish this incredibly useful analytical technique.READ MORE